CIS

Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

FDA, Health, General Health, Research, Pharmaceutical, Science, Thrombocytopenia, Patient, Death, NSE, Administration, Industry, CIS, Health, Pulmonary toxicity, Mission statement, Bleeding, Risk factor (finance), Risk, Leukopenia, West Pharmaceutical Services, Pandemic, Ingredient, Infection, Security (finance), Injection, USFDA, Epidemic, BSE, Mortality, Disease, Coronavirus, API, NYSE, Lists of disasters, RDY, Regulation of tobacco by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Use, Annual report, USP, Pain management, Dermatology, COVID-19, Generic drug, Pharmaceutical industry
Friday, October 15, 2021 - 6:40pm

The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

Key Points: 
  • The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.
  • Dr. Reddys Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.
  • Please click here for full prescribing information including boxed warning: https://www.drreddys.com/media/1019198/carmustine-for-inj-leaflet.pdf
    Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections.
  • Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1)].

Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara® Biosimilar

Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, EMA, View, Adalimumab, CIS, Pharmacy, NMPA, Ulcerative colitis, Biosimilar, Cancer, Trial of the century, European Medicines Agency, National Medical Products Administration, Light, Engineering, Therapy, Marketing, FDA, Patient, News, WeChat, Degenerative disease, Â, Intellectual property, Psoriatic arthritis, Forward-looking statement, Psoriasis, CEO, Drug development, MTX, Safety, Partnership, Ustekinumab, Autoimmunity, Generic drug, Pharmaceutical industry, Gasoline
Friday, October 15, 2021 - 1:08pm

Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.

Key Points: 
  • Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.
  • Pharmapark will be responsible for filing the dossier in Russia and other CIS countries.
  • This partnership will leverage Pharmaparks strong local presence, sales and marketing capabilities in Russia and other CIS countries.
  • Bio-Thera is pleased to expand our partnership with Pharmapark to commercialize our ustekinumab biosimilar program in Russia and other CIS countries, said Dr. Shengfeng Li, CEO of Bio-Thera.

Arriello Board Advisors Publish Timely Market Strategy Advice as Biotechs Review their International PV Obligations

EMA, PV, Organization, Sequah Medicine Company, Risk management, MHRA, CIS, Time, CIOMS, European Medicines Agency, Compliance, Alexion, J&J, ICH, FDA, Pharmaceutical medicine, MENA, Alexion Pharmaceuticals, Wyeth, Pharming, List of life sciences, Drug development, Advisory board, Pharmaceutical industry, Renewable energy, Medical device
Thursday, October 14, 2021 - 7:00pm

in New Jersey have highlighted the main differences between the US and European PV expectations, both pre- and post-market.

Key Points: 
  • in New Jersey have highlighted the main differences between the US and European PV expectations, both pre- and post-market.
  • The experts pooled their advice for ambitious young biotechs looking to capitalize on global opportunities when they typically lack the scale of PV resources of much larger life sciences companies.
  • "This latest guide, providing biotechs with timely PV advice and tips on internal market strategy planning, is another fantastic example of the value they add to Arriello and to our global client base.
  • These services include market consultancy, global regulatory affairs strategy and implementation, full and local pharmacovigilance solutions, clinical drug safety and quality and compliance auditing systems.

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ORR, Pancreatic cancer, OTCQB, Niemann–Pick disease, Hoag (health network), NPC, BCG, Cancer, CIS, RECIST, Los Angeles, Security (finance), NMIBC, GMP, CytRx, Dor, SEC, Therapy, Infection, Interleukin, FDA, DCR, College, PFS, Patient, Progression-free survival, Clinical trial, COVID-19 vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Food, U.S. Securities and Exchange Commission, Medicine, Company, Annual report, Phase II, Gaucher's disease, Immunotherapy, Cohort study, OS, Safety, Maintenance, Chan, NASDAQ, Research, III, COVID-19, Pharmaceutical industry, Management, Vaccine
Thursday, October 14, 2021 - 1:00pm

Of the 48 evaluable patients, 23 (48%) had extremely advanced disease upon enrollment (i.e.

Key Points: 
  • Of the 48 evaluable patients, 23 (48%) had extremely advanced disease upon enrollment (i.e.
  • This study was to explore if the Nant Cancer Vaccine could address this unmet need.
  • It is gratifying to note that patients in this study, who had progressed after up to six lines of prior therapy, have exceeded historical survival rates despite having very advanced pancreatic cancer upon enrollment.
  • This Phase 2, randomized, three-cohort, open-label study will evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic pancreatic cancer (NCT04390399).

Magnit and Largest FMCG Companies sign Code of Commitments under 'United for a Healthier Future' Initiative

Federal Project Number One, Goal, Food, LSE, PepsiCo, Procter & Gamble, Krasnodar, EMEA, Consumer Goods Forum, Industry, Solution, National Project (party), Awareness, Environment, CIS, GFK, Initiative, Health, Education, Smoking, FMCG, Ecology, CHL, Leadership, Code, Self-care, Boston Consulting Group, Community Care, CGF, MOEX, Quality of life, Company, Danone, Food safety, Pharmaceutical industry, Marketing, Convenience food
Thursday, October 14, 2021 - 12:08pm

Krasnodar, Russia (October 14, 2021): Magnit PJSC (MOEX and LSE: MGNT; the Company, Magnit), one of Russia's leading retailers, and eight international FMCG producers, has signed the Code of Voluntary Commitments under the "United for a Healthier Future" Initiative.

Key Points: 
  • Krasnodar, Russia (October 14, 2021): Magnit PJSC (MOEX and LSE: MGNT; the Company, Magnit), one of Russia's leading retailers, and eight international FMCG producers, has signed the Code of Voluntary Commitments under the "United for a Healthier Future" Initiative.
  • Besides Magnit, the Code was signed by Nestl, Johnson & Johnson Consumer Health, Danone, Mars, PepsiCo, L'Oral, Procter & Gamble, as well as Boston Consulting Group.
  • The Code was developed as part of the "United for a Healthier Future" Initiative, which was announced in April 2021.
  • "The adopted Code will serve as the foundation for the largest FMCG producers and retailers in taking care of the consumer and the world around us.

Tower Semiconductor to Hold its 2021 Annual Technical Global Symposium Online Event

RF, MEMS, Tower, Tower Semiconductor, Power management, Technology, AR, Silicon-germanium, Silicon, Solution, CIS, CMOS, Senior, General officer, Security (finance), Analog, AI, Power, Efficiency, BiCMOS, RF CMOS, Artificial intelligence, ICS, TASE, Time of flight, U.S. Securities and Exchange Commission, Lidar, Company, VR, Israel Securities Authority, NASDAQ, BCD, Neuromorphic engineering, Car, IDMS, Communication, F-4, F-3, Mobile phone
Wednesday, October 13, 2021 - 12:00pm

Presenting technology solutions and development roadmaps addressing the rising demands of the communication, automotive, medical, AI, advanced displays and industrial markets

Key Points: 
  • Presenting technology solutions and development roadmaps addressing the rising demands of the communication, automotive, medical, AI, advanced displays and industrial markets
    MIGDAL HAEMEK, Israel, October 13, 2021 Tower Semiconductor (NASDAQ/TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, today announced its online 2021 annual Technical Global Symposium.
  • In addition, Companys global manufacturing capabilities, solutions, and capacity growth programs will be presented.
  • Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release.
  • Tower Semiconductor Investor Relations Contact: Noit Levy | +972-4-604-7066 | noitle @towersemi.com

Rich Geruson, NexOptic Chairman, Announces Global Sales Distribution Agreement with NTek Device for NexOptic AI

Internet, Lexar, All Light, IDIS, Solution, FSE, NC, CMOS, GLOBE, Forward-looking statement, ARM, CIS, Intention, Risk, IOT, TSX, TSX Venture Exchange, Company, CEO, Ecosystem, Patent, Image, Technology, Senior, DSLR, AI, Intelligence, Samsung, Sensor, Communication, Partner, Sony, Name, Tyrannomyrmex alii, Industry, Artificial intelligence, Qualcomm, News, Antirrhinum, Â, Partnership, 3D printing, Television
Wednesday, October 13, 2021 - 3:35pm

NTek Device is an indispensable partner to a vast array of clients in mobile cameras, surveillance cameras, and automotive cameras.

Key Points: 
  • NTek Device is an indispensable partner to a vast array of clients in mobile cameras, surveillance cameras, and automotive cameras.
  • NTek is partnered with virtually all Korean camera image development firms and module manufacturers.
  • NTek has significant product distribution centres in Korea and Hong Kong and partnership distribution networks in Shenzhen, China and Taipei, Taiwan.
  • Its voluminous list of customers includes Partron and Powerlogics, as well as Korean leaders in video security with global reach.

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date

Research, Infectious Diseases, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, ORR, Pancreatic cancer, Vii, BCG, Hoag (health network), Private Securities Litigation Reform Act, Cancer, Time, RECIST, Radiation, Los Angeles, NMIBC, Mergers and acquisitions, GMP, Dor, SEC, Mortality, Infection, Interleukin, Therapy, FDA, DCR, PHASE 2, Patrick Soon-Shiong, PFS, College, Patient, Ix, Progression-free survival, Clinical trial, COVID-19 vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Forward-looking statement, Medicine, Phase II, CIS, Immunotherapy, Cohort study, OS, Safety, Maintenance, Chan, NASDAQ, III, COVID-19, Pharmaceutical industry, Vaccine
Wednesday, October 13, 2021 - 2:00pm

The majority of participants in the study to date remain on therapy and 90% (43/48) of the evaluable patients have exceeded the approximately two-month historical survival rate.

Key Points: 
  • The majority of participants in the study to date remain on therapy and 90% (43/48) of the evaluable patients have exceeded the approximately two-month historical survival rate.
  • had progressed after three to six prior lines of therapy) and, of these patients, 20 out of 23 (87%) have exceeded historical survival rates.
  • It is gratifying to note that patients in this study, who had progressed after up to six lines of prior therapy, have exceeded historical survival rates despite having very advanced pancreatic cancer upon enrollment.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

Private Securities Litigation Reform Act, Chugai Pharmaceutical Co., Streptococcus pyogenes, GMP, Therapy, IL-8, CIS, Cyst, VEGF, Streptococcus, Warfarin necrosis, COVID-19, IL-6, Food, GLOBE, Safety, Cancer, HIV disease progression rates, Microcystic lymphatic malformation, United States, Cytokine, FDA, U.S. Securities and Exchange Commission, LMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Interleukin, Neutrophil, Monocyte, United, Lymphocyte, Bladder cancer, Degenerative disease, IND, IL-12, Recurrence, NMIBC, Patient, Neoplasm, Risk, Nasdaq, Pharmaceutical industry
Tuesday, October 12, 2021 - 12:00pm

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). Protara expects to initiate a Phase 1 clinical trial of TARA-002 in adults with high-grade NMIBC by the end of 2021.

Key Points: 
  • Protara expects to initiate a Phase 1 clinical trial of TARA-002 in adults with high-grade NMIBC by the end of 2021.
  • We are seeing significant increases in recurrence and disease progression, as well as an escalating number of patients requiring cystectomies.
  • Bladder cancer is the 6th most common cancer intheUnited States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Cryptex Added Tether TRC20 To the Listing

DPO, KYC, CIS, USDT, ERC20, Cryptocurrency
Monday, October 11, 2021 - 7:33pm

Moscow, Russia--(Newsfile Corp. - October 11, 2021) - Anonymous cryptocurrency trading platform Cryptex added USDT based on TRC20 protocol to the listing.

Key Points: 
  • Moscow, Russia--(Newsfile Corp. - October 11, 2021) - Anonymous cryptocurrency trading platform Cryptex added USDT based on TRC20 protocol to the listing.
  • "TRC20 tokens use DPoS consensus algorithm, so the network works faster and transactions cost less money if we compare it with ERC20 tokens," explains a Cryptex representative.
  • "What is more important, USDT TRC20 opens up the possibility for users to make small trades at reasonable prices.
  • USDT TRC20 was assigned ticker USDTRX and enabled the following trading pairs: USDTRX/PM and USDTRX/USD .